A

ADC Therapeutics SA
D

ADCT

1.63000
USD
-0.04
(-2.40%)
Market Closed
Volume
14,565
EPS
-2
Div Yield
-
P/E
-1
Market Cap
157,604,076
Related Instruments
    C
    CIEN
    -2.370
    (-2.74%)
    84.080 USD
    CSCO
    CSCO
    -0.690
    (-1.07%)
    63.970 USD
    DELL
    DELL
    -2.300
    (-1.92%)
    117.620 USD
    HPE
    HPE
    -0.585
    (-2.69%)
    21.150 USD
    HPQ
    HPQ
    -0.060
    (-0.17%)
    34.655 USD
    IBM
    IBM
    -3.14
    (-1.18%)
    261.65 USD
    I
    INFN
    -0.00500
    (-0.08%)
    6.65000 USD
    INTC
    INTC
    -1.240
    (-4.75%)
    24.850 USD
    J
    JNPR
    -0.085
    (-0.24%)
    35.995 USD
    NTAP
    NTAP
    -0.100
    (-0.08%)
    124.480 USD
    More
News

Title: ADC Therapeutics SA

Sector: Healthcare
Industry: Biotechnology
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.